CHOLANGIOCARCINOMA

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard liver-directed chemotherapy can help people with certain cancers that have spread to the liver. About 70 adults with colorectal, bile duct, or adrenal cancer will receive treatment through a pump place…

This study tests whether using a special surgical glue (Glubran 2) during pancreas surgery can reduce the risk of a dangerous leak from the pancreas. About 194 adults with a soft pancreas who need surgery for cancer will be randomly assigned to receive the glue or standard care. …

This early-phase study tests a new drug called MGC028 in adults with advanced solid tumors (lung, bile duct, pancreas, or colon cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or stop them from g…

This study tests a new two-drug combination (trifluridine/tipiracil pills plus oxaliplatin IV) in 27 people with advanced biliary tract cancer whose first chemotherapy stopped working or didn't help. The goal is to see if this combo can keep the cancer from growing better than th…

This study tests a personalized radiation technique called PULSAR combined with two immunotherapy drugs and chemotherapy in 60 adults with advanced bile duct cancer. The goal is to see if this combination is safe and effective at controlling the disease. Participants must be 18-7…

This early-phase study tests whether adding heat therapy and a special type of radiation to standard chemoimmunotherapy is safe and feasible for people with advanced bile duct cancer that cannot be removed by surgery. About 15 participants will receive the standard drugs gemcitab…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety. About 10 participants will receive one of two dose lev…

This study tests a new drug called BOLD-100 combined with standard FOLFOX chemotherapy in people with advanced colorectal, pancreatic, stomach, or bile duct cancers. The goal is to see if the combination is safe and can shrink tumors or slow cancer growth. About 220 adults whose …

This study tests a new drug, APL-5125, in about 100 adults with advanced solid tumors like colorectal, pancreatic, and breast cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The trial has two pha…

This study tests whether a daily pill called ivosidenib can help keep bile duct cancer from returning after surgery and chemotherapy. It is for 40 adults with a specific gene mutation (IDH1) whose cancer was completely removed. Participants will take the drug for one year, and re…

This study tests a drug called tivozanib for people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink or slow the cancer. About 31 adults will take tivozanib p…

This study tests a combination of four drugs (gemcitabine, cisplatin, zimberelimab, and quemliclustat) as a first treatment for people with advanced bile duct cancer that has not spread or come back after prior therapy. About 33 to 39 participants will receive the drugs in cycles…

This study tests whether combining two targeted drugs, pemigatinib and afatinib, is safe and works against advanced solid tumors that have certain FGFR gene changes. About 70 adults whose cancers have not responded to standard treatments will take part. The goal is to find the be…

This study is for people with a type of bile duct cancer that cannot be removed by surgery or has spread. It combines three treatments: tiny radioactive beads placed in the liver (Y-90), an immunotherapy drug (durvalumab), and two chemotherapy drugs (gemcitabine and cisplatin). T…

This study is for people with a type of bile duct cancer called intrahepatic cholangiocarcinoma that can be removed with surgery. Researchers want to see if adding the immunotherapy drug pembrolizumab to standard chemotherapy (cisplatin and gemcitabine) before and after surgery h…

This early-stage study tests a new drug called LY4337713 in people with advanced cancers (like pancreatic, breast, ovarian, or colorectal) that have high levels of a protein called FAP. The drug delivers radiation directly to cancer cells. The main goals are to check safety, find…

This early-stage study tests a new drug called PHST001, alone or with chemotherapy, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the best dose. About 272 people with cancers like ovarian, end…

This study looks at how well the targeted drug ivosidenib works for adults with a rare and aggressive bile duct cancer that has a specific IDH1 mutation and has already been treated with at least one other therapy. Researchers will track how long the cancer stays under control, q…

This study tests whether taking spirulina tablets before and after liver surgery can help protect the liver and speed up recovery. Thirty adults with bile duct cancer will take either spirulina or a placebo for three weeks before and after their operation. Researchers will measur…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.

This study is for people with advanced bile duct cancer that cannot be removed by surgery. It tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus immunotherapy (anti-PD-1/PD-L1 antibodies) as a first treatment. The goal is to see if this combination is …

This study tests a new approach for people with a type of bile duct cancer that is difficult to remove with surgery. Participants receive a combination of targeted radiation, immunotherapy (tislelizumab), and chemotherapy before any surgery. The goal is to shrink the tumor enough…

This study tests a daily pill called ivosidenib in 220 adults with advanced bile duct cancer that has a specific gene change (IDH1 mutation). Participants must have already tried at least one other cancer treatment. The goal is to confirm the drug is safe and helps control the ca…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study tests a new combination of two drugs, GNS561 and trametinib, in people with advanced bile duct cancer that has a specific genetic change called a KRAS mutation. The cancer must have worsened after at least one round of standard chemotherapy. The goal is to see if the c…

This study aims to develop a new way to diagnose cholangiocarcinoma (bile duct cancer) by analyzing proteins in bile fluid. Researchers will compare the accuracy of this bile-based test with standard tissue biopsy in 200 adults who have bile duct narrowing. If successful, the app…

This study is testing a new type of PET scan that targets a protein called Trop2, found on many solid tumors. The goal is to see if this scan can find and stage cancers like bladder, lung, liver, and ovarian cancer better than current methods. About 400 adults with confirmed or s…

This study is developing a blood test that looks for tiny molecules called miRNAs to detect several types of digestive system cancers (like liver, pancreatic, and colon cancer) early. The goal is to create a simple, noninvasive screening tool that can be used for large population…

This study aims to develop a blood test that can accurately distinguish between two common types of liver cancer—hepatocellular carcinoma and cholangiocarcinoma—before surgery. Researchers will analyze tiny particles called exosomes in the blood using machine learning. The goal i…

This study is testing a new imaging agent called 18F-FSPG for PET scans to see if it can find liver cancer more accurately than current methods. About 110 adults with liver tumors will get this scan before their planned surgery or transplant. The goal is to improve diagnosis and …

This study is testing whether a new PET imaging tracer called [18F]FAPI-74 can find tumors as well as or better than the standard tracer in adults with certain cancers (like pancreatic, ovarian, or lung cancer). Participants will get both types of scans to compare how many tumors…

This study is testing a new type of PET/CT scan that uses a special tracer called 18F-T2 to find cancers that have high levels of a protein called CAIX. About 200 adults with cancers like kidney, bladder, lung, or breast cancer will get this scan to see if it works better than th…

This study is testing whether a new type of PET scan (68Ga-FAPI-46) can better detect the spread of pancreatic and bile duct cancers compared to standard CT and MRI scans. About 120 adults with newly diagnosed, potentially curable cancer will receive the new scan. If it proves mo…

This study collects tumor and normal tissue samples from people already scheduled for surgery or biopsy at the NIH Clinical Center. The goal is to provide researchers with biological material to discover new molecular targets for cancer therapies. Up to 1800 adults and children (…

This study is collecting tissue and fluid samples from 160 people with suspected bile duct, liver, or pancreatic cancers. Researchers want to learn more about these cancers to develop better ways to diagnose and treat them. Participants will give extra samples during their regula…

This study looks back at 1,200 patients who had a breathing tube placed during general anesthesia for non-throat surgeries. Researchers want to find out how often throat injuries like hoarseness or sore throat happen, what factors increase the risk, and how patients recover. The …

This study looks at how the cancer drug olutasidenib changes the way the body processes other medications. Researchers will give a mix of test drugs to 16 adults with IDH1-mutated cancers (like AML or certain brain tumors) and measure their levels in the blood before and after ol…

This study creates a collection of blood, urine, stool, and other samples from up to 9,150 people with cholestatic liver diseases like primary biliary cholangitis and primary sclerosing cholangitis. Researchers will use these samples and health data to better understand how these…

This study is for people with advanced bile duct cancer who are already scheduled to receive a combination of two drugs, lenvatinib and pembrolizumab. Researchers will collect blood and tumor samples to look for genetic markers that might predict who benefits most from this treat…

This study looks at how often a specific gene change (BAP1 mutation) occurs in people with certain cancers like eye melanoma, skin melanoma, kidney cancer, and others. Researchers will study 500 patients and their family members to understand cancer patterns and risk factors. The…

This study looks at whether taking a blood sample from the vein that drains directly from a liver or pancreas tumor gives more useful genetic information than a standard arm vein sample. About 15 adults scheduled for a biopsy will provide both samples, and researchers will compar…

This study is testing whether an artificial intelligence tool can help match cancer patients to clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer and use the AI to suggest trials. The goal is to see if this approa…

This study collects bile and bile duct cells from people with Primary Sclerosing Cholangitis (PSC) and healthy volunteers. Researchers will grow these cells into mini-organs called organoids to better understand how PSC progresses and how bile duct cancer develops. The goal is to…

This study looks at what causes biliary tree cancers by examining environmental, viral, and genetic factors. Researchers will study 1500 people, including patients and healthy volunteers, to find markers that predict cancer development and treatment response. The goal is to bette…